The OMEGA Clinical Trial

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Boston Scientific Corporation
ClinicalTrials.gov Identifier:
NCT01419171
First received: August 16, 2011
Last updated: July 24, 2014
Last verified: July 2014
  Purpose

The purpose of this study is to evaluate the safety and effectiveness of the OMEGA Coronary Stent System for the treatment of subjects with a de novo atherosclerotic coronary artery lesion.


Condition Intervention
Atherosclerosis
Coronary Artery Disease
Device: OMEGA™ Monorail Coronary Stent System

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: OMEGA: A Prospective, Multicenter Single-Arm Trial to Assess the OMEGA™ Coronary Stent System for the Treatment of a Single De Novo Coronary Artery Lesion

Resource links provided by NLM:


Further study details as provided by Boston Scientific Corporation:

Primary Outcome Measures:
  • 9-month Target Lesion Failure (TLF) Rate [ Time Frame: Nine Month ] [ Designated as safety issue: Yes ]
    The primary endpoint is 9-month target lesion failure (TLF) rate, defined as any ischemia-driven revascularization of the target lesion (TLR), Myocardial Infarction (MI) (Q-wave and non-Q-wave) related to the target vessel, or cardiac death.


Secondary Outcome Measures:
  • 12 Month Target Lesion Revascularization (TLR) Rate [ Time Frame: Participants will be followed for the duration of hospital stay, an expected average of 1 day, through 12 months ] [ Designated as safety issue: Yes ]
  • 12 Month Target Vessel Revascularization (TVR) Rate [ Time Frame: Participants will be followed for the duration of hospital stay, an expected average of 1 day, through 12 months ] [ Designated as safety issue: Yes ]
  • 12 Month Target Vessel Failure (TVF) Rate [ Time Frame: Participants will be followed for the duration of hospital stay, an expected average of 1 day, through 12 months ] [ Designated as safety issue: Yes ]
  • 12 Month Myocardial Infarction (MI)(Q-wave and Non-Q-wave) Rate [ Time Frame: Participants will be followed for the duration of hospital stay, an expected average of 1 day, through 12 months ] [ Designated as safety issue: Yes ]
  • 12 Month Cardiac Death Rate [ Time Frame: Participants will be followed for the duration of hospital stay, an expected average of 1 day, through 12 months ] [ Designated as safety issue: Yes ]
  • 12 Month Non-cardiac Death Rate [ Time Frame: Participants will be followed for the duration of hospital stay, an expected average of 1 day, through 12 months ] [ Designated as safety issue: Yes ]
  • 12 Month All Death Rate [ Time Frame: Participants will be followed for the duration of hospital stay, an expected average of 1 day, through 12 months ] [ Designated as safety issue: Yes ]
  • 12 Month Cardiac Death or MI Rate [ Time Frame: Participants will be followed for the duration of hospital stay, an expected average of 1 day, through 12 months ] [ Designated as safety issue: Yes ]
  • 12 Month All Death or MI Rate [ Time Frame: Participants will be followed for the duration of hospital stay, an expected average of 1 day, through 12 months ] [ Designated as safety issue: Yes ]
  • 12 Month All Death/MI/TVR Rate [ Time Frame: Participants will be followed for the duration of hospital stay, an expected average of 1 day, through 12 months ] [ Designated as safety issue: Yes ]
  • 12 Month Stent Thrombosis Rate (Definite or Probable by Academic Research Consortium [ARC] Definitions) [ Time Frame: Participants will be followed for the duration of hospital stay, an expected average of 1 day, through 12 months ] [ Designated as safety issue: Yes ]
  • Periprocedural Endpoints: Technical Success Rate [ Time Frame: Participants will be followed for the duration of hospital stay, an expected average of 1 day ] [ Designated as safety issue: Yes ]
  • Clinical Procedural Success Rate [ Time Frame: Participants will be followed for the duration of hospital stay, an expected average of 1 day ] [ Designated as safety issue: Yes ]

Enrollment: 328
Study Start Date: October 2011
Study Completion Date: January 2014
Primary Completion Date: October 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: OMEGA™ Monorail Coronary Stent System Device: OMEGA™ Monorail Coronary Stent System
All enrolled patients are treated with the OMEGA™ Monorail Bare Metal Coronary Stent System and followed for 12 months post-procedure.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subject must be at least 18 years of age.
  • Subject (or legal guardian) indicates understanding of the trial requirements and the treatment procedures and provides written informed consent before any trial-specific tests or procedures are performed.
  • Subject is eligible for percutaneous coronary intervention (PCI).
  • Subject has symptomatic coronary artery disease or documented silent ischemia.
  • Subject is an acceptable candidate for coronary artery bypass grafting (CABG).
  • Subject has a left ventricular ejection fraction (LVEF) ≥30% as measured within 60 days prior to enrollment.
  • Subject is willing to comply with all protocol-required follow-up evaluations.

Angiographic Inclusion Criteria:

  • Target lesion must be a de novo lesion located in a native coronary artery with a visually estimated reference vessel diameter (RVD) ≥ 2.25 mm and ≤4.5 mm.
  • Target lesion length must measure (by visual estimate) as follows:

    • ≤28 mm for stent diameter lengths of 2.75 mm, 3.00 mm, 3.50 mm, 4.00 mm and 4.50 mm
    • ≤24 mm for stent diameter lengths of 2.25 mm and 2.50 mm
  • Target lesion must be in a major coronary artery or branch with visually estimated stenosis ≥50% and <100% with Thrombolysis in Myocardial Infarction (TIMI) flow >1.
  • Target lesion must be successfully pre-dilated.

Exclusion Criteria:

  • Subject has clinical symptoms and/or electrocardiogram (ECG) changes consistent with acute myocardial infarction (MI).
  • Subject with unstable angina or recent MI (clinically diagnosed within 3 days) must have creatine kinase (CK)/ creatine kinase-myoglobin band(CK-MB) or troponin documented prior to the procedure and are excluded if any of the following criteria are met at the time of the index procedure:

    1. If CK MB >2× upper limit of normal (ULN), the subject is excluded regardless of the CK Total.
    2. If CK Total >2× ULN, CK-MB must be drawn and the subject is excluded if CK-MB is abnormal.
    3. If CK/CK-MB results are not available at the time of procedure, the subject is excluded if troponin >1× ULN and the subject has at least one of the following:

      • Subject has ischemic symptoms and ECG changes indicative of ongoing ischemia (e.g., >1 mm stent thrombosis (ST) segment elevation or depression in consecutive leads or new left bundle branch block [LBBB])
      • Development of pathological Q waves in the ECG or;
      • Imaging evidence of new loss of viable myocardium or new regional wall motion abnormality Note: Subjects who do not have unstable angina or recent MI must still have CK/CK-MB drawn prior to the index procedure. However, the results for these subjects do not need to be available prior to the index procedure and there are no exclusion criteria based on these studies.
  • Subject is receiving chronic (≥72 hours) anticoagulation therapy (e.g., heparin, coumadin) for indications other than acute coronary syndrome.
  • Subject has a platelet count <100,000 cells/mm3 or >700,000 cells/mm3.
  • Subject has a white blood cell (WBC) count <3,000 cells/mm3.
  • Subject has documented or suspected liver disease, including laboratory evidence of hepatitis.
  • Subject is on dialysis or has known renal insufficiency (e.g. serum creatinine level >2.0 mg/dL).
  • Subject has active peptic ulcer disease, an active gastrointestinal (GI) bleed, other bleeding diathesis or coagulopathy or will refuse transfusions.
  • Subject has had a cerebrovascular accident (CVA) or transient ischemic attack (TIA) within the past 6 months, or has any permanent neurologic defect that may cause non-compliance with the protocol.
  • Target vessel (including side branches) has been treated with any type of PCI (e.g., balloon angioplasty, stent, cutting balloon, atherectomy) within 12 months prior to the index procedure.
  • Target vessel has been treated within 10 mm proximal or distal to the target lesion (by visual estimate) with any type of PCI (e.g., balloon angioplasty, stent, cutting balloon, or atherectomy) at any time prior to the index procedure.
  • Non-target vessel or side branch has been treated with any type of PCI (e.g., balloon angioplasty, stent, cutting balloon, atherectomy) within 1 day prior to the index procedure.

Note: 1 lesion in a non-target vessel may be treated during the index procedure prior to the treatment of the target (study) lesion.

  • Planned or actual target vessel treatment with an unapproved device, directional or rotational coronary atherectomy, laser, cutting balloon, or transluminal extraction catheter immediately prior to stent placement.
  • Planned PCI or CABG after the index procedure.
  • Subject previously treated at any time with coronary intravascular brachytherapy.
  • Subject has known allergy to the study stent system or protocol-required concomitant medications (e.g., stainless steel, platinum, chromium, nickel, iron, thienopyridines and acetylsalicylic acid (ASA)) and contrast (that cannot be adequately premedicated).
  • Subject has any other serious medical illness (e.g., cancer, congestive heart failure) that may reduce life expectancy to less than 12 months.
  • Subject has current problems with substance abuse (e.g., alcohol, cocaine, heroin, etc.).
  • Subject has a planned procedure that may cause non-compliance with the protocol or confound data interpretation.
  • Subject is participating in another investigational drug or device clinical trial that has not reached its primary endpoint or intends to participate in another investigational drug or device clinical trial within 12 months after the index procedure.
  • Subject is female of childbearing potential with a positive pregnancy test within 14 days before the index procedure, is lactating, or intends to become pregnant during the study.
  • Subject has more than 1 target lesion, or more than 1 target lesion and 1 non-target lesion, which will be treated during the index procedure.

Angiographic Exclusion Criteria:

  • Target lesion meets any of the following criteria:

    • Aorto-ostial location (i.e., lesion located within 5 mm of the ostium by visual estimate)
    • Left main location
    • Located within 5 mm of the origin of the left anterior descending (LAD) coronary artery or left circumflex (LCX) coronary artery or Right Coronary Artery (RCA) by visual estimate
    • Located within a saphenous vein graft or an arterial graft
    • Will be accessed via a saphenous vein graft or an arterial graft
    • Involves a side branch ≥2.0 mm in diameter by visual estimate
    • Involves a side branch <2.0 mm in diameter by visual estimate that has a clinically significant stenosis at the ostium
    • TIMI flow 0 (total occlusion) or TIMI flow 1 prior to guide wire crossing
    • Excessive tortuosity proximal to or within the lesion
    • Extreme angulation proximal to or within the lesion
    • Target lesion and/or target vessel proximal to the target lesion is moderately to severely calcified by visual estimate
    • Restenotic from previous intervention
    • Thrombus, or possible thrombus, present in the target vessel
    • Target lesion cannot be covered by a single study stent (unplanned bailout stenting is allowed)
  • Non-target lesion to be treated during the index procedure meets any of the following criteria:

    • Located within the target vessel
    • Located within a bypass graft (venous or arterial)
    • Left main location
    • Chronic total occlusion
    • Involves a complex bifurcation (e.g., bifurcations requiring treatment with more than 1 stent)
    • Requires additional unplanned stents (treatment of the non-target lesion with more than one stent is permitted as long as the stents are initially planned)
    • Treatment not deemed a clinical angiographic success
    • Treatment not completed prior to treatment of target lesion
  • Subject has unprotected left main coronary artery disease (>50% diameter stenosis).
  • Subject has protected left main coronary artery disease and a target lesion in the LAD or LCX.
  • Subject has an additional clinically significant lesion(s) in the target vessel for which an intervention within 12 months after the index procedure may be required.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01419171

  Hide Study Locations
Locations
United States, Arkansas
National Park Medical Center
Hot Springs, Arkansas, United States, 71901
Arkansas Heart Hospital
Little Rock, Arkansas, United States, 72211
United States, California
Loma Linda University Medical Center
Loma Linda, California, United States, 92354
United States, Florida
Florida Hospital
Orlando, Florida, United States, 32803
Sarasota Memorial Hospital
Sarasota, Florida, United States, 34239
United States, Illinois
Southern Illinois University-Memorial Medical Center
Springfield, Illinois, United States, 62702
United States, Indiana
St. Vincent's Hospital
Indianapolis, Indiana, United States, 46260
United States, Kentucky
St. Joseph Hospital
Lexington, Kentucky, United States, 40504
United States, Maryland
Union Memorial Hospital
Baltimore, Maryland, United States, 21218
United States, Minnesota
St. Mary's Duluth Clinic Regional Heart Center
Duluth, Minnesota, United States, 55805
Regions Hospital
St. Paul, Minnesota, United States, 55101
United States, New Jersey
Our Lady of Lourdes Medical Center
Cherry Hill, New Jersey, United States, 08034
United States, New Mexico
Presbyterian Hospital
Albuquerque, New Mexico, United States, 87106
United States, North Carolina
Wake Medical Center
Raleigh, North Carolina, United States, 27610
United States, Ohio
The Carl & Edyth Lindner Center for Research and Education at The Christ Hospital
Cincinnati, Ohio, United States, 45219
Ohio State University Medical Center
Columbus, Ohio, United States, 43210
Mercy St. Vincent Medical Center
Toledo, Ohio, United States, 43608
The Toledo Hospital
Toledo, Ohio, United States, 43606
United States, Oklahoma
Oklahoma Heart Hospital
Oklahoma City, Oklahoma, United States, 73120
United States, Pennsylvania
Presbyterian University of Pennsylvania Medical Center
Philidelphia, Pennsylvania, United States, 01910
United States, Vermont
Fletcher Allen Health Care
Burlington, Vermont, United States, 05401
United States, West Virginia
St. Mary's Medical Center
Huntington, West Virginia, United States, 25701
Belgium
Imelda Ziekenhuis
Bonheiden, Belgium, 2820
Universitair Ziekenhuis Gent
Gent, Belgium, 9000
Virga Jesse Ziekenhuis
Hasselt, Belgium, 3500
H-Hartziekenhuis Roeselare-Menen vzw
Roeselare, Belgium, 8800
France
Centre Hôpital Universitaire Rangueil
Toulouse, Cedex 9, France, 31059
Hospitaux du Haut Leveque
Pessac, Cedex, France, 33604
Clinique Pasteur
Toulouse Cedex 3, France, 31076
Germany
Kerckhoff Heart and Thoraxcenter
Bad, Nauheim, Germany, 61231
Herz-Kreislauf-Zentrum Segeberger Kliniken GmbH
Bad Segeberg, Germany, 23795
Universitaetsklinikum Heidelberg
Heidelberg, Germany, 69120
Latvia
P. Stradins University Hospital
Riga, Latvia, LV-1002
Netherlands
Haga Ziekenhuis locatie Leyweg
Den Haag, Netherlands, 2545 CH
Catharina Ziekenhuis
Eindhoven, Netherlands, 5623 EJ
Acadmisch Ziekehus
Maastricht, Netherlands, 6202AZ
Spain
Hospital Clinico Y Provincial
Barcelona, Spain, 08036
Sponsors and Collaborators
Boston Scientific Corporation
Investigators
Study Director: Peter Maurer, MPH Boston Scientific Corporation
  More Information

No publications provided

Responsible Party: Boston Scientific Corporation
ClinicalTrials.gov Identifier: NCT01419171     History of Changes
Other Study ID Numbers: S2215
Study First Received: August 16, 2011
Results First Received: July 24, 2014
Last Updated: July 24, 2014
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Atherosclerosis
Arteriosclerosis
Coronary Artery Disease
Myocardial Ischemia
Coronary Disease
Arterial Occlusive Diseases
Vascular Diseases
Cardiovascular Diseases
Heart Diseases

ClinicalTrials.gov processed this record on August 28, 2014